alisertib Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Alisertib (MLN8237) is an orally available selective aurora A kinase inhibitor developed by Takeda. It was investigated as a treatment for relapsed or refractory peripheral T-cell lymphoma. Development was abandoned in 2015 due to poor clinical trial results.   Wikipedia

Chemistry

  • SMILES: COc1cccc(F)c1C2=NCc3cnc(Nc4ccc(C(=O)O)c(OC)c4)nc3c5ccc(Cl)cc25
  • InChIKey: ZLHFILGSQDJULK-UHFFFAOYSA-N
  • Mol. Mass: 518.93
  • ALogP: 5.75
  • ChEMBL Molecule:
    alisertib  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

alisertib | alsertib | mln8237 | mln 8237 | mln-8237

Organizations (31)

Research & Development (31)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (74)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (74)


 

Adenocarcinoma (Phase 1)

Astrocytoma (Phase 1)

Brain Neoplasms (Phase 1)

Breast Neoplasms (Phase 2)

Burkitt Lymphoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Colonic Neoplasms (Phase 1)

Colorectal Neoplasms (Phase 1)

Digestive System Neoplasms (Phase 1)

Enteropathy-Associated T-Cell Lymphoma (Phase 1)

Ependymoma (Phase 1)

Esophageal Neoplasms (Phase 1/Phase 2)

Fallopian Tube Neoplasms (Phase 2)

Fibrosarcoma (Phase 2)

Glioblastoma (Phase 1)

Glioma (Phase 1)

Gliosarcoma (Phase 1)

Hamartoma (Phase 2)

Head and Neck Neoplasms (Phase 1)

Hepatoblastoma (Phase 2)

Hodgkin Disease (Phase 1)

Intestinal Neoplasms (Phase 1)

Intraocular Lymphoma (Phase 1)

Kidney Neoplasms (Phase 2)

Leiomyosarcoma (Phase 2)

Leukemia, Hairy Cell (Phase 1)

Leukemia, Large Granular Lymphocytic (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia-Lymphoma, Adult T-Cell (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Liposarcoma (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 1)

Lymphoma, B-Cell (Phase 1)

Lymphoma, B-Cell, Marginal Zone (Phase 2)

Lymphoma, Follicular (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Large-Cell, Anaplastic (Phase 2)

Lymphoma, Large-Cell, Immunoblastic (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Lymphoma, Primary Cutaneous Anaplastic Large Cell (Phase 1)

Lymphoma, T-Cell (Phase 3)

Lymphomatoid Granulomatosis (Phase 1)

Melanoma (Phase 1)

Mesothelioma (Phase 2)

Multiple Myeloma (Phase 1/Phase 2)

Mutation (Phase 1)

Myelodysplastic Syndromes (Phase 2)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 1/Phase 2)

Neoplasms, Germ Cell and Embryonal (Phase 2)

Nerve Sheath Neoplasms (Phase 2)

Neuroblastoma (Phase 2)

N-Myc Proto-Oncogene Protein (Phase 1)

Oligodendroglioma (Phase 1)

Osteosarcoma (Phase 2)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 1)

Postmenopause (Phase 2)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Prostatic Neoplasms (Phase 2)

Rhabdoid Tumor (Phase 2)

Rhabdomyosarcoma (Phase 2)

Sarcoma (Phase 2)

Sarcoma, Ewing (Phase 2)

Sezary Syndrome (Phase 1)

Small Cell Lung Carcinoma (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 1/Phase 2)

Testicular Neoplasms (Phase 1)

Urinary Bladder Neoplasms (Phase 2)

Waldenstrom Macroglobulinemia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 62
  • # of Trial Organizations: 31

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue